Apparatus and method for delivery of antimicrobial during a transdermal sampling and delivery process
11219390 · 2022-01-11
Assignee
Inventors
Cpc classification
A61B5/157
HUMAN NECESSITIES
A61B5/15134
HUMAN NECESSITIES
A61B5/150969
HUMAN NECESSITIES
A61B5/14514
HUMAN NECESSITIES
International classification
A61B5/145
HUMAN NECESSITIES
A61B5/157
HUMAN NECESSITIES
Abstract
A device for introducing at least one antimicrobial in an exposed region of a user's skin caused while accessing interstitial fluid includes a substrate having thereon at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion for forming a micropore in the user's skin. A nanofiber mat loaded with at least one antimicrobial material is arranged on the substrate such that it contacts the user's skin and encircles an opening of the micropore formed by the microheating element. In a preferred embodiment, the at least one antimicrobial material is LL-37.
Claims
1. A device for introducing at least one antimicrobial in an exposed region of a user's skin caused while accessing interstitial fluid of a user comprising: a first substrate having thereon multiple, individually electrically controllable microheating elements including at least a microheater portion with multiple electrodes connected to the microheater portion for accessing the interstitial fluid of the user, the first substrate including multiple first holes therethough which are aligned with the microheater portion of each of the microheating elements; and a second substrate having a nanofiber material containing at least one antimicrobial applied thereto in the form of multiple individual annulus-shaped nanofiber mats, the second substrate further including multiple second holes therethrough which are aligned with the microheater portion of each of the microheating elements, wherein each of the multiple annulus-shaped nanofiber mats surrounds one of the multiple second holes; the second substrate further including an adhesive material applied between each of the nanofiber mats to adhere the device to the user's skin; wherein the nanofiber material, the adhesive material, the second substrate, the first substrate and the microheating elements are arranged in the following order in the device: first, the nanofiber material and the adhesive material which are configured to contact the user's skin; second, the second substrate; third, the first substrate; and fourth, the microheating elements.
2. The device of claim 1, wherein one of the at least one antimicrobial is LL-37.
3. The device of claim 1, wherein the nanofiber mat includes the at least one antimicrobial and at least one additional antimicrobial material therein.
4. The device of claim 3, wherein the at least two antimicrobial materials are arranged in individual rings comprising the annulus-shaped nanofiber mat.
5. The device of claim 1, wherein each annulus-shaped nanofiber mats has a width of between 5 to 25 μm.
Description
BRIEF SUMMARY OF THE FIGURES
(1) The Summary of the Embodiments, as well as the following Detailed Description, is best understood when read in conjunction with the following exemplary drawings:
(2)
(3)
(4)
(5)
(6)
(7)
DETAILED DESCRIPTION
(8)
(9) The applied voltage specifications, i.e., volts/time, may vary in accordance with patient age and size. For example, devices used on adult human patients may be configured to apply 3V (with respect to ground) for, e.g., 30 msec, resulting in a rapid ablation of a portion of the patient's stratum corneum creating an approximately 50 μm diameter micropore therein. Whereas, the same or a different device, may be configured for use with premature human patients where the stratum corneum has minimal thickness. In this case, one skilled in the art recognizes that the applied voltage, time and resulting pore diameter would be reduced.
(10) Further, while the specific representative embodiments described and illustrated herein include the nanofiber mat 18 as being part of the microheating element 10, one skilled in the relevant art understands that variations which provide for the nanofiber mat 18 being in close proximity to the resulting micropore 16, but not necessarily on the microheating element 10, fall well within the scope of the present embodiments. For example, referring to
(11) Additional details regarding the formulation, layout, dimensions and operation of the microheating element 10 are described in the co-owned patents and patent applications (collectively, “Patent Documents”) listed in the Background section above. Multiple microheating elements 10 may be used in an array as discussed in the Patent Documents, wherein multiple individual microheating elements 10 each having a nanofiber mat 18 on or associated therein are included in an array. The array may be included on a substrate, e.g., patch, wherein each of the individual microheating elements 10 is individually controllable/usable, thus resulting in multiple micropores over the course of time and use of the array.
(12)
(13)
(14) Alternatively, the device may be a single-use device. Whether the microheating element is part of a single-use device or a multi-use device, the effectiveness of the nanofiber mat 18 or more specifically, the antimicrobial, may be enhanced by keeping the device in place for a predetermined amount of time, e.g., at least 2 hours, or an approximate amount of time calculated for the micropore 16 in the stratum corneum to begin closing up.
(15) A description of exemplary processes for formation of the nanofiber mat for use in the embodiment described herein may be found in one or more of the documents listed in the section Documents Incorporated by Reference. The immobilization of antimicrobial peptides and peptide motifs on nanofiber membranes has been achieved and the effectiveness of the antimicrobial nanofiber membranes as both an antibiotic and a wound healing facilitation material has been determined. In a specific exemplary embodiment, the nanofiber mat 18 may be formed using electrospinning techniques to generate nanofibers having varying diameters, e.g., 100-500 nm, from a solution of poly(ethylene-oxide) (PEO) and the antimicrobial peptide, LL-37 as discussed in detail in J. W. Gatti et al., Using electrospun poly(ethylene-oxide) nanofibers for improved retention and efficacy of bacteriolytic antibiotics, Biomed Microdevices, October 2013, Volume 15, Issue 5, pp 887-893.
(16) The antimicrobial LL-37 is selected as the exemplar microbial herein for its broad bacteria killing ability. More specifically, LL-37 has been shown to kill the following bacteria as discussed in Vandamme et al., “A comprehensive summary of LL-37, the factotum human cathelicidin peptide,” Cellular Immunology 280, pgs. 22-35 (2012): Bacillus anthracis; Enterococcus faecalis; Group A streptococcus; Group B Streptococcus; Lactobacillus casei; Listeria monocytogenes; Micrococcus luteus; Nocardia sp.; Propionibacterium acnes; Staphylococcus aureus; Streptococcus mutans; Streptococcus pneumonia; Borrelia spp.; Mycobacterium bovis; Mycobacterium smegmatis; Mycobacterium tuberculosis; Achromobacter xylosoxidans; Acinetobacter baumannii; Aggregatibacter actinomycetemcomitans; Brucella suis; Burkholderia pseudomallei; Burkholderia cepacia; Burkholderia thailandensis; Capnocytophaga spp.; Escherichia coli; Francisella novicida; Fusobacterium nucleatum; Haemophilus influenza; Helicobacter pylori; Klebsiella pneumonia; Leptospira interrogans; Mannheimia haemolytica; Pasteurella multocida; Porphyromonas circumdentaria; Porphyromonas gingivalis; Prevotella intermedia; Prevotella loescheii; Prevotella melaninogenica; Pseudomonas aeruginosa; Salmonella sp.; Shigella sp.; Stenotrophomonas maltophilia; Tannerella forsythia; Treponema denticola; Treponema pallidum and Yersinia pestis.
(17) One skilled in the art readily recognizes that other antimicrobials may be used, either alone, or in combination with LL-37 to cover a wider range of bacteria.
(18) The incorporation of an antimicrobial is also contemplated with respect to, e.g., a hand-held device for electrochemically monitoring an analyte in interstitial fluid of a user, such as that disclosed in co-owned U.S. patent application Ser. No. 13/835,696. Components of an exemplary device 34 are illustrated in
(19) Although not shown, connective elements located e.g. in the inner wall of device 34 can serve to place elements 37, 39, and/or 50 (as described below) in contact with the controllable voltage source 38.
(20) With further reference to
(21) While the particular examples above are directed to certain exemplary transdermal devices, one skilled in the art appreciates that the antimicrobial nanofiber mat or coating may be incorporated into other medical equipment that invades the body, including, but not limited to syringes, catheters, etc.
(22) As referenced briefly in the Background, the risk of infection at surgical and other wound sites dressed with sutures and/or other closure materials is an on-going concern. The antimicrobial nanofiber materials referenced above may form or be incorporated into various dressings including, but not limited to biodegradable fibrous mesh, biodegradable suture (e.g., a polymer) or non-biodegradable suture (e.g., silk nanofibers) containing LL-37 or other antimicrobial. As with the nanofiber mats described herein, these dressings form a barrier to foreign bodies.